103 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- InsermFR26 papers
- Sorbonne UniversitéFR23 papers
- Université Paris CitéFR20 papers
- Assistance Publique – Hôpitaux de ParisFR11 papers
- Centre National de la Recherche ScientifiqueFR10 papers
- Heka : Méthodes basées sur les données et modèles en santé pour l'acquisition de connaissancesFR9 papers
- Centre de Mathématiques Appliquées de l'École polytechniqueFR8 papers
- École PolytechniqueFR8 papers
- Institut national de recherche en sciences et technologies du numériqueFR8 papers
- Sorbonne Paris CitéFR7 papers
- Institut du CerveauFR6 papers
- Hôpital Européen Georges-PompidouFR4 papers
7 papers · 1 filter
FedECA: Federated External Control Arms for Causal Inference with Time-To-Event Data in Distributed Settings
Jean Ogier du Terrail, Quentin Klopfenstein, Honghao Li +22
External control arms can inform early clinical development of experimental drugs and provide efficacy evidence for regulatory approval. However, accessing sufficient real-world or…
Bayesian Framework for Multi-Source Data Integration -- Application to Human Extrapolation From Preclinical Studies
Sandrine Boulet, Moreno Ursino, Robin Michelet +4
In preclinical investigations, e.g. in in vitro, in vivo and in silico studies, the pharmacokinetic, pharmacodynamic and toxicological characteristics of a drug are evaluated befor…
A straightforward meta-analysis approach for oncology phase I dose-finding studies
Christian Röver, Moreno Ursino, Tim Friede +1
Phase I early-phase clinical studies aim at investigating the safety and the underlying dose-toxicity relationship of a drug or combination. While little may still be known about t…
Bayesian dose-regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
Emma Gerard, Sarah Zohar, Hoai-Thu Thai +3
Phase I dose-finding trials in oncology seek to find the maximum tolerated dose (MTD) of a drug under a specific schedule. Evaluating drug-schedules aims at improving treatment saf…
Optimisation des parcours patients pour lutter contre l'errance de diagnostic des patients atteints de maladies rares
Frédéric Logé, Rémi Besson, Stéphanie Allassonnière
A patient suffering from a rare disease in France has to wait an average of two years before being diagnosed. This medical wandering is highly detrimental both for the health syste…
Personalized Dynamic Treatment Regimes in Continuous Time: A Bayesian Approach for Optimizing Clinical Decisions with Timing
William Hua, Hongyuan Mei, Sarah Zohar +2
Accurate models of clinical actions and their impacts on disease progression are critical for estimating personalized optimal dynamic treatment regimes (DTRs) in medical/health res…
Simulation of virtual cohorts increases predictive accuracy of cognitive decline in MCI subjects
Igor Koval, Stéphanie Allassonnière, Stanley Durrleman
The ability to predict the progression of biomarkers, notably in NDD, is limited by the size of the longitudinal data sets, in terms of number of patients, number of visits per pat…